Outlook Therapeutics Reports Financial Results for Fiscal Year 2020 and Provides Corporate Update

MONMOUTH JUNCTION, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a?late clinical-stage?biopharmaceutical company?working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg?for use in retinal?indications, today announced its corporate highlights and financial results for its fiscal year ended September 30, 2020.

Original post:
Outlook Therapeutics Reports Financial Results for Fiscal Year 2020 and Provides Corporate Update

Related Post